Strategic cooperation between AstraZeneca and Medochemie Far East

Cypriot pharmaceutical company Medochemie has teamed up with AstraZeneca in a collaboration that will see the production and packaging processes for innovative pharmaceutical products of the British-Swedish pharmaceutical giant transferred to Medochemie Far East in Vietnam.

A relevant certificate has been issued by the Ministry of Science and Technology of Vietnam to facilitate the cooperation.

Chairman and CEO of AstraZeneca Vietnam, Nitin Kapoor stated that AstraZeneca is committed to closely cooperate and enhance healthcare capacity, develop the domestic pharmaceutical industry; thereby aiming to provide patients with easy access to high-quality drugs produced in the country.

According to the Director of Medochemie Far East, Gregory Charitonos, “Medochemie is delighted to be a partner of AstraZeneca in advancing Vietnam's pharmaceutical industry. We view this collaboration as a pivotal step in our joint efforts and remain committed to working closely together to foster the development of Vietnam's pharmaceutical and healthcare sectors.”

Medochemie Far East operates 5 high-tech pharmaceutical manufacturing plants in Vietnam that occupy a total area of 63,500 square meters of 9 different product lines, specialised in technology transfer. The manufactured tech-transferred, high-quality products are exported to Europe and other countries worldwide as well as supplied in the local market.

Medochemie was established in 1976 in Cyprus by Dr Andreas Pittas. It has since expanded from its base in Europe, to the Middle East & Africa, through to the Far East and the Americas. Outside its 21 core offices, it developed a network of trusted agents and partners allowing it to operate in 107 countries.

Today, Medochemie Ltd has thirteen manufacturing plants and facilities. Nine are in Cyprus, one in the Netherlands, and three in Vietnam. It has acquired and maintains 4,355 marketing authorisation licences for 630 different pharmaceutical products, classified in over 10 therapeutic categories. It employs 1,880 people and is a founding member of Medicines for Europe (former EGA).